Free Trial

Evaxion A/S (EVAX) Competitors

Evaxion A/S logo
$6.29 +0.57 (+9.97%)
Closing price 10/8/2025 04:00 PM Eastern
Extended Trading
$6.25 -0.04 (-0.57%)
As of 10/8/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EVAX vs. TAOX, NEUP, HOTH, CLSD, CING, APLM, CTXR, SYBX, FNCH, and PRPH

Should you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Synaptogenix (TAOX), Neuphoria Therapeutics (NEUP), Hoth Therapeutics (HOTH), Clearside Biomedical (CLSD), Cingulate (CING), Apollomics (APLM), Citius Pharmaceuticals (CTXR), Synlogic (SYBX), Finch Therapeutics Group (FNCH), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

Evaxion A/S vs. Its Competitors

Evaxion A/S (NASDAQ:EVAX) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Evaxion A/S has higher revenue and earnings than Synaptogenix. Evaxion A/S is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion A/S$3.34M2.64-$10.57M-$1.32-4.77
Synaptogenix$3.96K6,732.85-$12.77M-$20.16-0.38

Synaptogenix's return on equity of -277.76% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion A/SN/A -319.52% -63.56%
Synaptogenix N/A -277.76%-150.79%

Evaxion A/S has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 74.88%. Given Evaxion A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evaxion A/S is more favorable than Synaptogenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Evaxion A/S had 2 more articles in the media than Synaptogenix. MarketBeat recorded 4 mentions for Evaxion A/S and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 beat Evaxion A/S's score of -0.19 indicating that Synaptogenix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evaxion A/S
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Synaptogenix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Evaxion A/S beats Synaptogenix on 10 of the 15 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ Exchange
Market Cap$8.02M$2.30B$6.10B$10.55B
Dividend YieldN/AN/A5.69%4.75%
P/E Ratio-4.7737.9485.4727.60
Price / Sales2.6445.58601.78232.87
Price / CashN/A61.4237.9261.55
Price / Book-5.3313.6013.136.76
Net Income-$10.57M-$63.46M$3.30B$275.88M
7 Day Performance32.70%4.71%4.29%2.81%
1 Month Performance124.64%8.57%9.45%9.24%
1 Year Performance-53.06%49.52%86.64%35.42%

Evaxion A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion A/S
2.1556 of 5 stars
$6.29
+10.0%
$11.00
+74.9%
-55.7%$8.02M$3.34M-4.7760Gap Up
TAOX
Synaptogenix
0.0567 of 5 stars
$6.11
-2.7%
N/AN/A$21.31M$3.96K-0.304Positive News
Analyst Forecast
NEUP
Neuphoria Therapeutics
1.8315 of 5 stars
$11.33
-4.5%
$28.00
+147.1%
N/A$21.30M$15.66M0.00N/AAnalyst Downgrade
HOTH
Hoth Therapeutics
1.5788 of 5 stars
$1.60
-3.3%
$4.00
+150.8%
+99.5%$21.15MN/A-1.494Analyst Forecast
Gap Up
CLSD
Clearside Biomedical
2.8554 of 5 stars
$4.03
-4.2%
$63.00
+1,465.2%
-80.2%$21.09M$1.66M-0.7330
CING
Cingulate
2.3462 of 5 stars
$3.82
-1.8%
$26.25
+587.0%
-6.4%$20.67MN/A-0.9320News Coverage
Analyst Forecast
APLM
Apollomics
0.3879 of 5 stars
$18.43
flat
N/A+29.8%$20.33MN/A0.0045Analyst Forecast
Gap Up
CTXR
Citius Pharmaceuticals
2.0032 of 5 stars
$1.19
+0.8%
$53.00
+4,353.8%
-86.8%$20.24MN/A0.0020Analyst Forecast
Gap Down
SYBX
Synlogic
N/A$1.65
-2.9%
N/A+18.8%$19.32M$10K-20.6480News Coverage
Positive News
Analyst Forecast
FNCH
Finch Therapeutics Group
0.7817 of 5 stars
$12.00
-2.0%
N/A+5.2%$19.27MN/A-1.36190
PRPH
ProPhase Labs
0.4315 of 5 stars
$0.45
+3.5%
N/A-77.8%$18.82M$5.59M-0.36130Analyst Forecast
Gap Up

Related Companies and Tools


This page (NASDAQ:EVAX) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners